We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Read MoreHide Full Article
Key Takeaways
Precigen's Papzimeos generated $74.6 million in revenues in the first six months of 2026.
PGEN's long-term growth prospects hinge on Papzimeos expansion as well as its AdenoVerse pipeline.
Ironwood's U.S. Linzess net profit share surged 72.6% year over year in the first half of 2026.
Precigen (PGEN - Free Report) and Ironwood Pharmaceuticals (IRWD - Free Report) are biotech firms that depend largely on the successful commercialization of a single key drug while trying to broaden their relatively limited pipelines. Each company continues to rely heavily on its marketed product to build a strong presence in its respective therapeutic area.
While Precigen is engaged in developing innovative precision medicines for difficult-to-treat diseases through its AdenoVerse platform, Ironwood is more focused on its key gastrointestinal (GI) disorder drug and a pipeline targeting rare GI conditions.
Precigen’s sole marketed drug, Papzimeos (zopapogene imadenovec-drba), is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). Ironwood’s sole marketed drug, Linzess, is approved for the treatment of certain patients with irritable bowel syndrome with constipation and functional constipation.
But which one makes for a better investment pick today? Let's examine the fundamentals of the two stocks to make a prudent choice.
The Case for PGEN Stock
Papzimeos has demonstrated strong early commercial momentum since its approval and launch in 2025. In the first six months of 2026, the product generated $74.6 million in revenues. Importantly, product revenues from Papzimeos sales more than doubled sequentially during the second quarter of 2026.
The drug provides Precigen with a differentiated commercial position and a potentially durable revenue base. Sales are expected to grow steadily as Precigen expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Papzimeos.
Precigen is also pursuing additional growth opportunities outside the United States. A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe.
Meanwhile, Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals (INO - Free Report) is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application seeking approval for INO-3107 in RRP is currently under review in the United States. A decision from the FDA is expected on Oct. 30, 2026. A potential nod will induce acute competition for Precigen in the future quarters.
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in HPV-driven cancers.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
The Case for IRWD Stock
Ironwood’s top line primarily comprises revenues recorded through its collaborative arrangements with AbbVie related to the development and commercialization of Linzess in the United States.
The company markets Linzess in the United States in collaboration with AbbVie, while equally sharing Linzess’ brand collaboration profits and losses in the United States. The drug continues to demonstrate healthy prescription demand growth and has treated millions of patients since launch.
Linzess sales have witnessed a significant surge in 2026, subsequently boosting Ironwood’s share of net profits from sales of the partnered drug in the United States. Ironwood’s share of net profit from sales of Linzess in the United States surged 72.6% year over year during the first six months of 2026.
Also, Ironwood is regularly getting approvals to expand Linzess' label, which is also supporting sales growth. Additionally, Linzess is well protected by patents and is not expected to face generic competition before March 2029.
Reflecting the higher demand for Linzess, Ironwood raised its full-year 2026 revenue guidance. The company now expects total revenues to be in the range of $460 to $485 million in 2026 compared with the previous expectation of $450 to $475 million.
Ironwood is developing its next-generation GLP-2 analog, apraglutide, for treating patients with short bowel syndrome (“SBS”) with intestinal failure (“IF”) who are dependent on parenteral support (“PS”). In June 2026, the company initiated the confirmatory phase III STARS-2 study, which is currently recruiting participants.
Despite the encouraging outlook, Ironwood’s heavy reliance on a single product remains a concern. Additionally, any delay or setback in the development of apraglutide could weigh on its long-term growth visibility.
How Do Estimates Compare for PGEN & IRWD?
The Zacks Consensus Estimate for Precigen’s 2026 sales and earnings per share (EPS) implies a year-over-year increase of around 2,484.7% and 117.5%, respectively. Bottom-line estimates for 2026 have improved. EPS estimates for 2027 have also been trending upward over the past 60 days.
PGEN Estimate Movement
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Ironwood’s 2026 sales and earnings per share (EPS) implies a year-over-year increase of around 57.6% and 816.7%, respectively. EPS estimates for 2026 have been trending upward, while loss per share estimates for 2027 have been stable over the past 60 days.
IRWD Estimate Movement
Image Source: Zacks Investment Research
Price Performance and Valuation of PGEN & IRWD
Year to date, shares of PGEN have surged 92.6%, while those of IRWD have risen 23.5%. In comparison, the industry has increased 8.9%, as seen in the chart below.
Image Source: Zacks Investment Research
Precigen looks more expensive than Ironwood, going by the price-to-sales (P/S) ratio. PGEN’s shares currently trade at 38.85 times trailing sales value, higher than 1.79 for IRWD.
Image Source: Zacks Investment Research
PGEN vs. IRWD: Which Stock Holds the Edge?
Between the two stocks discussed above, Precigen sports a Zacks Rank #1 (Strong Buy) and can be backed as the better pick over Ironwood, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Precigen’s strong performance in the first half of 2026 is likely to continue in the second half. Growth in Papzimeos sales should continue to boost the top line. The company is making good progress in its pipeline development and successful data readouts from the same should further aid the stock.
Despite a premium valuation, Precigen’s recent price rally and rising earnings estimates also indicate analysts' optimistic outlook for the stock. Although Linzess sales have been rising on the back of underlying demand, Ironwood’s high reliance on a single drug reflects the company’s vulnerability to competitive risks.
Overall, PGEN offers a clearer growth outlook, making it a better pick than IRWD for investors seeking meaningful gains in both the short and long term.
View the Zacks #1 Rank List
Image: Bigstock
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
Key Takeaways
Precigen (PGEN - Free Report) and Ironwood Pharmaceuticals (IRWD - Free Report) are biotech firms that depend largely on the successful commercialization of a single key drug while trying to broaden their relatively limited pipelines. Each company continues to rely heavily on its marketed product to build a strong presence in its respective therapeutic area.
While Precigen is engaged in developing innovative precision medicines for difficult-to-treat diseases through its AdenoVerse platform, Ironwood is more focused on its key gastrointestinal (GI) disorder drug and a pipeline targeting rare GI conditions.
Precigen’s sole marketed drug, Papzimeos (zopapogene imadenovec-drba), is currently the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). Ironwood’s sole marketed drug, Linzess, is approved for the treatment of certain patients with irritable bowel syndrome with constipation and functional constipation.
But which one makes for a better investment pick today? Let's examine the fundamentals of the two stocks to make a prudent choice.
The Case for PGEN Stock
Papzimeos has demonstrated strong early commercial momentum since its approval and launch in 2025. In the first six months of 2026, the product generated $74.6 million in revenues. Importantly, product revenues from Papzimeos sales more than doubled sequentially during the second quarter of 2026.
The drug provides Precigen with a differentiated commercial position and a potentially durable revenue base. Sales are expected to grow steadily as Precigen expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Papzimeos.
Precigen is also pursuing additional growth opportunities outside the United States. A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe.
Meanwhile, Papzimeos benefits from seven years of FDA market exclusivity through Aug. 14, 2032. Combined with its first-in-class position and lack of an approved competing therapy for adult RRP, this protection allows Precigen to establish a durable commercial franchise before potential competitors enter the market.
Inovio Pharmaceuticals (INO - Free Report) is developing its lead candidate, INO-3107, a DNA-based immunotherapy as a treatment for RRP.
Inovio’s biologics license application seeking approval for INO-3107 in RRP is currently under review in the United States. A decision from the FDA is expected on Oct. 30, 2026. A potential nod will induce acute competition for Precigen in the future quarters.
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in HPV-driven cancers.
Precigen plans to provide an update on the broader AdenoVerse portfolio, including PRGN-2009, by the end of 2026.
The Case for IRWD Stock
Ironwood’s top line primarily comprises revenues recorded through its collaborative arrangements with AbbVie related to the development and commercialization of Linzess in the United States.
The company markets Linzess in the United States in collaboration with AbbVie, while equally sharing Linzess’ brand collaboration profits and losses in the United States. The drug continues to demonstrate healthy prescription demand growth and has treated millions of patients since launch.
Linzess sales have witnessed a significant surge in 2026, subsequently boosting Ironwood’s share of net profits from sales of the partnered drug in the United States. Ironwood’s share of net profit from sales of Linzess in the United States surged 72.6% year over year during the first six months of 2026.
Also, Ironwood is regularly getting approvals to expand Linzess' label, which is also supporting sales growth. Additionally, Linzess is well protected by patents and is not expected to face generic competition before March 2029.
Reflecting the higher demand for Linzess, Ironwood raised its full-year 2026 revenue guidance. The company now expects total revenues to be in the range of $460 to $485 million in 2026 compared with the previous expectation of $450 to $475 million.
Ironwood is developing its next-generation GLP-2 analog, apraglutide, for treating patients with short bowel syndrome (“SBS”) with intestinal failure (“IF”) who are dependent on parenteral support (“PS”). In June 2026, the company initiated the confirmatory phase III STARS-2 study, which is currently recruiting participants.
Despite the encouraging outlook, Ironwood’s heavy reliance on a single product remains a concern. Additionally, any delay or setback in the development of apraglutide could weigh on its long-term growth visibility.
How Do Estimates Compare for PGEN & IRWD?
The Zacks Consensus Estimate for Precigen’s 2026 sales and earnings per share (EPS) implies a year-over-year increase of around 2,484.7% and 117.5%, respectively. Bottom-line estimates for 2026 have improved. EPS estimates for 2027 have also been trending upward over the past 60 days.
PGEN Estimate Movement
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Ironwood’s 2026 sales and earnings per share (EPS) implies a year-over-year increase of around 57.6% and 816.7%, respectively. EPS estimates for 2026 have been trending upward, while loss per share estimates for 2027 have been stable over the past 60 days.
IRWD Estimate Movement
Image Source: Zacks Investment Research
Price Performance and Valuation of PGEN & IRWD
Year to date, shares of PGEN have surged 92.6%, while those of IRWD have risen 23.5%. In comparison, the industry has increased 8.9%, as seen in the chart below.
Image Source: Zacks Investment Research
Precigen looks more expensive than Ironwood, going by the price-to-sales (P/S) ratio. PGEN’s shares currently trade at 38.85 times trailing sales value, higher than 1.79 for IRWD.
Image Source: Zacks Investment Research
PGEN vs. IRWD: Which Stock Holds the Edge?
Between the two stocks discussed above, Precigen sports a Zacks Rank #1 (Strong Buy) and can be backed as the better pick over Ironwood, which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Precigen’s strong performance in the first half of 2026 is likely to continue in the second half. Growth in Papzimeos sales should continue to boost the top line. The company is making good progress in its pipeline development and successful data readouts from the same should further aid the stock.
Despite a premium valuation, Precigen’s recent price rally and rising earnings estimates also indicate analysts' optimistic outlook for the stock. Although Linzess sales have been rising on the back of underlying demand, Ironwood’s high reliance on a single drug reflects the company’s vulnerability to competitive risks.
Overall, PGEN offers a clearer growth outlook, making it a better pick than IRWD for investors seeking meaningful gains in both the short and long term.